Comparative Pharmacology
Head-to-head clinical analysis: AUROVELA 24 FE versus VIORELE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUROVELA 24 FE versus VIORELE.
AUROVELA 24 FE vs VIORELE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive. Norethindrone acetate suppresses gonadotropin release (FSH and LH) via progestogenic activity, inhibiting ovulation. Ethinyl estradiol provides negative feedback on hypothalamic-pituitary axis, further suppressing gonadotropins and stabilizing endometrium.
VIORELE is a monoclonal antibody that binds to and inhibits the activity of interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in the pathogenesis of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
One tablet (0.10 mg ethinyl estradiol / 1.0 mg norethindrone acetate) orally once daily for 24 days, followed by 4 days of ferrous fumarate 75 mg tablets (placebo). Administer at the same time each day without interruption.
50 mg orally once daily
None Documented
None Documented
Norethindrone: 7-8 hours; Ethinyl estradiol: 13-16 hours. Steady-state achieved within 5 days.
Terminal elimination half-life of 12–15 hours (mean 13.5 h) in healthy adults; may be prolonged in renal impairment (up to 30 h).
Norethindrone: ~40% renal, ~60% fecal; Ethinyl estradiol: ~40% renal, ~60% fecal as glucuronide and sulfate conjugates.
Primarily renal (unchanged drug and metabolites, ~60%) and fecal (~30%), with minor biliary contribution (~10%).
Category C
Category C
Oral Contraceptive
Oral Contraceptive